Setting a new standard for the treatment of chronic inflammation.

Press Releases

Catch up on the latest news from Evommune.

September 3, 2024

Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
July 16, 2024

Evommune Announces Positive Proof-of-Concept Clinical Trial Results for its MRGPRX2 Antagonist (EVO756)
June 24, 2024

Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio
March 20, 2024

Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 in Greater China and Key Asian Countries
January 18, 2024

Evommune Announces Initation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria
November 28, 2023

Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
September 27, 2023

Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan
June 28, 2023

Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team
April 26, 2023

Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases
October 3, 2022

Evommune Announces Appointment of Dr. Jeegar Patel as Chief Scientific Officer

We have a range of chronic inflammatory disease programs currently in development.

See Our Pipeline